Clinuvel Pharmaceuticals Limited
CLVLYOTCHealthcare● Active
$6.73
+$0.13(+2.01%)
Market Cap$339153780
P/E Ratio—
52W High$9
52W Low$5.98
Clinuvel Pharmaceuticals Limited (CLVLY) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CLVLY · earnings · updated Jun 9, 2026
Latest Earnings
Q1 FY2026Report Date: Feb 25, 2026EPS Actual
$0.15
Est. $0.20 · -25.9%
Revenue
$0.03B
Est. $0.03B · +2.2%
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Feb 25, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
CLVLY reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Sep 1, 2026 | $0.34 | — | — | — | $0.04B | — |
| ▼ Q1 FY2026 | Feb 25, 2026 | $0.20 | $0.15 | -25.9% | $0.03B | $0.03B | +2.2% |
| ▲ Q3 FY2025 | Aug 21, 2025 | $0.18 | $0.29 | +57.4% | $0.04B | $0.04B | -3.1% |
| ▲ Q1 FY2025 | Feb 26, 2025 | $0.14 | $0.17 | +27.1% | $0.02B | $0.02B | +2.1% |
| ▲ Q3 FY2024 | Aug 28, 2024 | $0.30 | $0.33 | +10.4% | $0.04B | $0.04B | +0.9% |
| ▼ Q1 FY2024 | Feb 22, 2024 | $0.17 | $0.14 | -15.7% | $0.02B | $0.02B | -4.8% |
| ▼ Q2 FY2023 | Jun 30, 2023 | $0.25 | $0.25 | -2.6% | $0.03B | $0.03B | -4.7% |
| ▼ Q4 FY2022 | Dec 31, 2022 | $0.17 | $0.15 | -11.9% | $0.02B | $0.02B | -10.8% |
Q3 FY2026
Sep 1, 2026
EPS Actual
—
EPS Est.
$0.34
EPS Surpr.
—
Revenue
—
Q1 FY2026
Feb 25, 2026Miss
EPS Actual
$0.15
EPS Est.
$0.20
EPS Surpr.
-25.9%
Revenue
$0.03B
Q3 FY2025
Aug 21, 2025Beat
EPS Actual
$0.29
EPS Est.
$0.18
EPS Surpr.
+57.4%
Revenue
$0.04B
Q1 FY2025
Feb 26, 2025Beat
EPS Actual
$0.17
EPS Est.
$0.14
EPS Surpr.
+27.1%
Revenue
$0.02B
Q3 FY2024
Aug 28, 2024Beat
EPS Actual
$0.33
EPS Est.
$0.30
EPS Surpr.
+10.4%
Revenue
$0.04B
Q1 FY2024
Feb 22, 2024Miss
EPS Actual
$0.14
EPS Est.
$0.17
EPS Surpr.
-15.7%
Revenue
$0.02B
Q2 FY2023
Jun 30, 2023Miss
EPS Actual
$0.25
EPS Est.
$0.25
EPS Surpr.
-2.6%
Revenue
$0.03B
Q4 FY2022
Dec 31, 2022Miss
EPS Actual
$0.15
EPS Est.
$0.17
EPS Surpr.
-11.9%
Revenue
$0.02B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q1 FY2026 | Feb 25, 2026 | -25.9% | $8.44 | $8.24 | -2.37% |
| ▲ Q3 FY2025 | Aug 21, 2025 | +57.4% | $7.58 | $7.82 | +3.17% |
| ▲ Q1 FY2025 | Feb 26, 2025 | +27.1% | $7.12 | $7.17 | +0.70% |
| ▲ Q3 FY2024 | Aug 28, 2024 | +10.4% | $9.24 | $9.43 | +2.06% |
| ▼ Q1 FY2024 | Feb 22, 2024 | -15.7% | $10.52 | $9.39 | -10.74% |
| ▼ Q2 FY2023 | Jun 30, 2023 | -2.6% | $11.82 | $11.98 | +1.35% |
| ▼ Q4 FY2022 | Dec 31, 2022 | -11.9% | $14.74 | $14.55 | -1.29% |
| ▼ Q2 FY2022 | Jun 30, 2022 | -6.1% | $10.34 | $10.27 | -0.68% |
Q1 FY2026-2.37%
Report Date
Feb 25, 2026
EPS Beat/Miss
-25.9%
Price Before
$8.44
Price After
$8.24
Q3 FY2025+3.17%
Report Date
Aug 21, 2025
EPS Beat/Miss
+57.4%
Price Before
$7.58
Price After
$7.82
Q1 FY2025+0.70%
Report Date
Feb 26, 2025
EPS Beat/Miss
+27.1%
Price Before
$7.12
Price After
$7.17
Q3 FY2024+2.06%
Report Date
Aug 28, 2024
EPS Beat/Miss
+10.4%
Price Before
$9.24
Price After
$9.43
Q1 FY2024-10.74%
Report Date
Feb 22, 2024
EPS Beat/Miss
-15.7%
Price Before
$10.52
Price After
$9.39
Q2 FY2023+1.35%
Report Date
Jun 30, 2023
EPS Beat/Miss
-2.6%
Price Before
$11.82
Price After
$11.98
Q4 FY2022-1.29%
Report Date
Dec 31, 2022
EPS Beat/Miss
-11.9%
Price Before
$14.74
Price After
$14.55
Q2 FY2022-0.68%
Report Date
Jun 30, 2022
EPS Beat/Miss
-6.1%
Price Before
$10.34
Price After
$10.27
Avg Beat Reaction+1.98%
Avg Miss Reaction-2.75%
Beat Rate3 / 8 quarters
Largest Move-10.74% (Q1 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CLVLY ends December
Clinuvel Pharmaceuticals Limited (CLVLY) most recently reported earnings on February 25, 2026 for Q1 FY2026, posting EPS of $0.15 — missing the analyst consensus of $0.20 by -25.9%. The next CLVLY earnings date is expected around September 1, 2026.
Each quarter, investors track CLVLY earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CLVLY revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CLVLY's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CLVLY earnings · 5 questionsClinuvel Pharmaceuticals Limited's next earnings report is expected around September 1, 2026. CLVLY typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CLVLY historically reports after market close (AMC).
CLVLY earnings datewhen is CLVLY earningsCLVLY next earnings datewhen does CLVLY report earningsCLVLY earnings calendar
▸ Source: FMP · Clinuvel Pharmaceuticals Limited SEC filings · US GAAP · Clinuvel Pharmaceuticals Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026